Life Sciences Technology Services

Aprio provides specialized biotechnology accounting, tax, audit, and life sciences advisory services for companies operating in biotech, digital health, medical devices, and pharmaceutical sectors. Our services include ASC 606 revenue recognition, financial reporting, technical accounting, R&D tax credit optimization, and global tax compliance. We also support multi-entity accounting, transaction readiness, and scalable financial infrastructure to help life sciences technology companies meet investor expectations and regulatory requirements while scaling efficiently.

We support biotech, digital health, medical device, and pharma innovators from pre-revenue through commercialization with integrated life science accounting, tax services, and advisory. Our team designs scalable accounting frameworks, establishes internal controls, and supports ASC 606 revenue recognition policies as companies move toward commercialization. We also assist with R&D tax credits, financial reporting, and investor-ready financial statements so you can focus on innovation while maintaining compliance and operational readiness.

Aprio helps life sciences technology companies interpret and implement ASC 606 revenue recognition standards across complex contract structures common in biotech, pharma, and digital health organizations. We analyze licensing agreements, milestone payments, and multi-element contracts to align revenue policies with both compliance requirements and growth strategies. This approach reduces the risk of restatements while strengthening confidence among investors, auditors, and regulators.

Yes. We provide buy-and-sell-side diligence, tax planning, technical accounting, and strategic guidance for biotechnology, medical device, digital health, and pharma companies preparing for M&A or IPO. At Aprio, we align life sciences technology tax services and financial strategy to long-term growth and liquidity goals.

Yes. Aprio supports digital health companies with integrated accounting, tax, and life sciences technology advisory services that help scale operations responsibly. Our team helps organizations build financial infrastructure, improve reporting processes, and manage regulatory compliance risks associated with rapid growth.

A specialized medical device audit helps ensure accuracy while navigating strict regulatory and compliance requirements. Aprio understands the operational and accounting complexities common in medical device manufacturing, product development, and global distribution. Through assurance and risk evaluation, we help organizations strengthen controls, improve transparency, and maintain compliance with industry regulations.

Yes. We provide multi-entity accounting, intercompany reconciliations, and consolidation services for global biotech and pharma organizations. Our frameworks support accurate reporting, scalable growth, and regulatory compliance for complex international operations.

Aprio delivers comprehensive biotechnology accounting and life sciences tax services that evolve with a company’s growth. We support early-stage startups, venture-backed biotech firms, and global pharmaceutical companies with tax compliance, transfer pricing strategies, and cross-border IP structuring. By aligning tax planning with expansion, funding, and liquidity strategies, we help life sciences technology companies manage risk while improving their global tax position.

We guide life sciences technology companies through IPO and public company readiness by addressing technical accounting, preparing draft financial statements, strengthening internal controls, and coordinating life sciences audit and pharma audit services. Our team supports SEC reporting and works alongside management to help ensure a disciplined transition to public-company standards.

We identify eligible R&D activities across biotechnology, digital health, medical device, and pharma operations. We calculate federal and state credits and integrate incentives into broader life sciences technology tax services, to help improve cash flow while reducing compliance risk.